Bepotastine tosylate  (Synonyms: 甲苯磺酸贝托司汀；甲苯磺酸贝他斯汀；甲苯磺酸贝托斯汀；甲苯磺酸贝他司汀)

Bepotastine tosylate is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine tosylate can suppress the expression of nerve growth factor (NGF). Bepotastine tosylate can be used in studies of allergic rhinitis, allergic conjunctivitis and urticaria/pruritus^[1][2][3][4].

Histamine H1 Receptor^[1][2][3][4].

Bepotastine tosylate (10, 100, 1000 µM; preincubates for 120 min) decreases the release of histamine induced by A23187 treatment, which reaches a statistically significant reduces level at 1000 µM^[1].
Bepotastine tosylate (50 µM; 1 h) suppresses the expression of NGF mRNA in NHEKs^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bepotastine tosylate (10 g/L; eye drop; 3 times at intervals of 20 min in one eye) demonstrates significant inhibition of PAF-induced conjunctival eosinophil infiltration^[1].
Bepotastine tosylate (3 mg/kg; p.o.; once) suppresses scratching behavior to a frequency of 59.0 and a duration of 14.57 seconds, which are almost the same levels compares with the control^[3].
Bepotastine tosylate (10 mg/kg; p.o.; once) significantly suppresses serum LTB 4 levels to 711.3 pg/mL at 1 h and 858.8 pg/mL at 2 h in NC/Nga mice with a rash^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

561.09

C₂₈H₃₃ClN₂O₆S

1160415-45-1

甲苯磺酸贝托司汀；甲苯磺酸贝他斯汀；甲苯磺酸贝托斯汀；甲苯磺酸贝他司汀

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kida T, et al. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010 Jul;91(1):8  [Content Brief]

  [2]. Kamata Y, et al. Bepotastine besilate downregulates the expression of nerve elongation factors in normal human epidermal keratinocytes. J Dermatol Sci. 2018 Apr 23:S0923-1811(18)30186-5.  [Content Brief]

  [3]. Tanizaki H, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol. 2008;145(4):277-82.  [Content Brief]

  [4]. Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38.  [Content Brief]